简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm

2025-09-12 01:37

NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. 

Kuehn Law, PLLC (PRNewsfoto/Kuehn Law, PLLC)

According to a federal securities lawsuit, DexCom insiders caused the company to misrepresent or fail to disclose material information concerning expected revenue for the fiscal year 2024. On July 25, 2024, Dexcom announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on their execution of "several key strategic initiatives" which "did not meet [their] high standards." On this news, DexCom's stock price fell to $64.00, a decline of about 40.66%.

If you currently own DXCM and purchased prior to April 28, 2023 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™ 

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Kuehn Law, PLLC

Justin Kuehn, Esq.

53 Hill Street, Suite 605

Southampton, NY 11968

justin@kuehn.law

(833) 672-0814

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-dexcom-inc-to-contact-law-firm-302554064.html

SOURCE Kuehn Law, PLLC

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。